As the first wave of China’s homegrown new medicines begins to reach the market — from Chi-Med’s fruquintinib to Junshi’s toripalimab — they have also appeared to set the scene for the domination of oncology drugs in the biopharma pipeline.
In a post capturing Chinese biopharma’s “Cambrian Explosion” — a reference to the geological time period that marked a dramatic burst of evolutionary changes in life on Earth, courtesy of WuXi AppTec’s Steve Yang — Frank Le Deu, head of China healthcare at McKinsey, highlighted a classic herd effect:
In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 47,800+ biopharma pros who read Endpoints News by email every day.Free Subscription